^
    12d
    Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma. (PubMed, medRxiv)
    DOC1021 was safe, feasibly integrated within SOC, and associated with more favorable outcomes in this challenging patient population. Patients who received observation rather than reoperation for worsening MRI contrast-enhancement exhibited superior survival, suggesting an immune-reactive tumor microenvironment manifesting as pseudo-progression. These data supported initiation of a randomized Phase II trial ( NCT06805305 ) for nGBM.
    P1 data • Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)
    11ms
    DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Diakonos Oncology Corporation | Active, not recruiting --> Recruiting | N=43 --> 18 | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment open • Enrollment change • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)
    over1year
    DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)
    over2years
    Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma (clinicaltrials.gov)
    P1, N=17, Completed, The Cooper Health System | Recruiting --> Completed | Trial completion date: Dec 2025 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    dubodencel (DOC1021)
    over2years
    DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Recruiting, Baylor College of Medicine
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)